Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MULTIPLE SCLEROSIS

Comparative effectiveness of rituximab in multiple sclerosis

Nature Reviews Neurology volume 17, pages 3–4 (2021)Cite this article

Subjects

B cell-depleting agents are emerging as important disease-modifying drugs for multiple sclerosis, but their effectiveness in relation to established treatments remains uncertain. To cast light on this issue, several studies have provided head-to-head comparisons of the anti-CD20 antibody rituximab with natalizumab, fingolimod and dimethyl fumarate in patients with multiple sclerosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vollmer, B. L. et al. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann. Clin. Transl Neurol. https://doi.org/10.1002/acn3.51111 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Alping, P. et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann. Neurol. 79, 950–958 (2016).

    Article  CAS  Google Scholar 

  3. Boremalm, M. et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. Eur. J. Neurol. 26, 1060–1067 (2019).

    Article  CAS  Google Scholar 

  4. Granqvist, M. et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 75, 320–327 (2018).

    Article  Google Scholar 

  5. Scotti, B. et al. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 13, e0197415 (2018).

    Article  Google Scholar 

  6. Roos, I. et al. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain https://doi.org/10.1093/brain/awaa231 (2020).

    Article  PubMed  Google Scholar 

  7. Austin, P. C. & Stuart, E. A. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat. Methods Med. Res. 26, 1654–1670 (2017).

    Article  Google Scholar 

  8. Funk, M. J. et al. Doubly robust estimation of causal effects. Am. J. Epidemiol. 173, 761–767 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

    Tomas Kalincik

  2. Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

    Tomas Kalincik

  3. Department of Health Sciences (DISSAL), Biostatistics Unit, University of Genoa, Genoa, Italy

    Maria Pia Sormani

  4. Ospedale Policlinico San Martino — IRCCS, Genoa, Italy

    Maria Pia Sormani

Authors
  1. Tomas Kalincik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Pia Sormani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomas Kalincik.

Ethics declarations

Competing interests

T.K. is the chair of the MSBase Scientific Leadership Group, has served on scientific advisory boards for Roche, Celgene, Sanofi Genzyme, Novartis, Merck and Biogen and the steering committee for Brain Atrophy Initiative by Sanofi Genzyme, has received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva, BioCSL and Merck and has received research support from Biogen. M.P.S. has received consulting fees from Biogen, Sanofi Genzyme, Roche, Novartis, Merck, GeNeuro, Celgene, TEVA and Medday.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalincik, T., Sormani, M.P. Comparative effectiveness of rituximab in multiple sclerosis. Nat Rev Neurol 17, 3–4 (2021). https://doi.org/10.1038/s41582-020-00412-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-020-00412-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing